Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
2.
Pharmaceuticals (Basel) ; 16(10)2023 Sep 27.
Article in English | MEDLINE | ID: mdl-37895841

ABSTRACT

Alzheimer's disease (AD) is the most common form of neurodegenerative disorders worldwide. Its pathologic features include massive neuroinflammation with abnormal deposition of ß-amyloid peptide in the cerebral tissues leading to degeneration of the brain neurons. Adverse effects associated with the traditional drugs used for the treatment of this pathological condition have directed the research efforts towards searching for alternative effective agents with minimal adverse effects. The aim of this study was to elucidate the potential ameliorative effects of dapagliflozin and/or hesperidin on Alzheimer's disease (AD) induced by lipopolysaccharide (LPS) injection in rats. In a rodent model of AD, the effect of dapagliflozin with or without hesperidin on the biochemical parameters and the behavioral tests as well as the histopathological parameters was determined. Each of dapagliflozin and hesperidin restored the behavioral tests to the reference values, augmented the antioxidant defense mechanisms, ameliorated the neuronal inflammatory responses, combatted the changes in Toll-like receptor-4 (TLR-4)/High-mobility group box 1 (HMGB1) protein signaling and receptors of advanced glycation end products (RAGE) levels, and restored the balance between the apoptotic signals and autophagy in the hippocampal tissues. Additionally, both agents exhibited an outstanding ability to combat LPS-induced perturbations in the histopathological and electron microscopic image of the brain tissues. These favorable effects were significantly encountered in the group treated with dapagliflozin/hesperidin combination when compared versus animals treated with either dapagliflozin or hesperidin. In conclusion, inhibition of the hippocampal HMGB1/TLR4/RAGE signaling, the pro-inflammatory axis, and apoptosis alongside augmentation of the antioxidant defenses and autophagy can be regarded as beneficial effects by which dapagliflozin/hesperidin combination may combat LPS-triggered AD.

3.
Pharmaceuticals (Basel) ; 15(5)2022 May 13.
Article in English | MEDLINE | ID: mdl-35631426

ABSTRACT

Colitis is one of the inflammatory states that affect the intestinal wall and may even predispose to malignancy due to chronic irritation. Although the etiology of colitis is not yet fully explored, a combination of genetic and environmental factors is strongly incriminated. Perindopril is an angiotensin-converting enzyme inhibitor that is used for the management of a wide range of cardiovascular diseases. Ambrosin is a sesquiterpene lactone that was proven to have beneficial effects in disorders characterized by inflammatory nature. The objective of this study is to make a comparison between the effects of perindopril or ambrosin on dextran sulfate sodium (DSS)-induced colitis in mice and to explore the effect of their combination. The present findings indicate that each ambrosin or perindopril alone or in combination is able to ameliorate oxidative stress and suppress the proinflammatory pathways in the colonic tissues of DSS-treated mice via mechanisms related to toll-like receptor 4/nuclear factor kappa B signaling and modulation of peroxisome proliferator-activated receptor gamma/sirtuin-1 levels. In addition, each ambrosin or perindopril alone or in combination inhibits apoptosis and augments the mediators of autophagy in DSS-treated mice. These effects are reflected in the amelioration of the histopathological and electron microscopic changes in the colonic tissues. Interestingly, the most remarkable effects are those encountered with the perindopril/ambrosin combination compared to the groups treated with each of these agents alone. In conclusion, the perindopril/ambrosin combination might represent an effective modality for mitigation of the pathogenic events and the clinical sequelae of colitis.

4.
Life Sci ; 295: 120396, 2022 Apr 15.
Article in English | MEDLINE | ID: mdl-35157909

ABSTRACT

AIMS: The objectives of this work were to assess the possibility of administration of omarigliptin and/or galangin to combat lipopolysaccharide (LPS)-induced neuroinflammation in rats and to explore the possible mechanisms that might contribute to their actions. MATERIALS AND METHODS: In a rat model of LPS-induced neuroinflammation, the changes in the behavioral tests, biochemical parameters, and the histopathological picture were assessed. KEY FINDINGS: Administration of either omarigliptin or galangin to LPS-injected rats was able to significantly improve the behavioral changes with restoration of the oxidant/antioxidant balance, decrement of toll-like receptor-4 levels, and amelioration of the neuroinflammation associated with inhibition of apoptosis and restoration of glucagon-like peptide-1 levels in the cerebral tissues. In addition, omarigliptin and/or galangin significantly reduced the levels of phospho-Akt and glycogen synthase kinase 3 beta (GSK-3ß) and significantly increased the expression of beclin-1 in the cerebral tissues compared versus the group treated with LPS alone. As a result, these changes were positively reflected on the histopathological and the electron microscopic picture of the cerebral tissues. These beneficial effects were maximally evidenced in rats treated with omarigliptin/galangin combination relative to the use of either omarigliptin or galangin alone. SIGNIFICANCE: Omarigliptin/galangin combination might be proposed as a promising therapeutic line for mitigation of the pathophysiologic events of LPS-induced neuroinflammation.


Subject(s)
Flavonoids/pharmacology , Heterocyclic Compounds, 2-Ring/pharmacology , Neuroinflammatory Diseases/drug therapy , Pyrans/pharmacology , Animals , Apoptosis/physiology , Drug Therapy, Combination/methods , Flavonoids/metabolism , Glucagon-Like Peptide 1/metabolism , Glycogen Synthase Kinase 3 beta/metabolism , Heterocyclic Compounds, 2-Ring/metabolism , Inflammation/pathology , Lipopolysaccharides/adverse effects , Male , Microglia/metabolism , Neuroinflammatory Diseases/physiopathology , Proto-Oncogene Proteins c-akt/metabolism , Pyrans/metabolism , Rats , Rats, Wistar , Signal Transduction/drug effects , Toll-Like Receptor 4/metabolism
5.
Asian Pac J Cancer Prev ; 20(12): 3723-3728, 2019 Dec 01.
Article in English | MEDLINE | ID: mdl-31870114

ABSTRACT

BACKGROUND: Skin hyperpigmentation usually results from an increased number, or activity, of melanocytes. The degree of pigmentation of skin depends on the amount and type of melanin, degree of skin vascularity, presence of carotene, and thickness of the stratum corneum. Common causes of hyperpigmentation include post-inflammatory hyperpigmentation, melasma, solar lentigines, ephelides (freckles), and café-au-lait macules. Some skin tumors can be hyperpigmented as basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and malignant melanoma (MM). Stem cell factor (SCF) is a growth factor and its interaction with its receptor, c-kit, is well known to be critical to the survival of melanocytes. METHODS: This study was carried out on 60 patients complaining of hyperpigmented skin lesions (20 melasma, 20 solar lentigines, and 20 freckles) and 36 patients with skin tumors (14 BCC, 12 SCC, and 10 MM). Punch skin biopsies were taken from the previous lesions. Immunohistochemical staining of these samples was done using the stem cell factor (SCF). RESULTS: There was positive expression of SCF in all cases of melasma, solar lentigines and freckles with significant increase in the intensity of expression in the lesional areas than the non-lesional ones (P=0.004). There was also a statistically significant increase in the expression of SCF in BCC and melanoma tumor cells. CONCLUSION: SCF has a great role in skin hyperpigmented disorders and this can be used as a target for the developing of new antipigmentary lines of treatment by inhibiting SCF. SCF can also be involved in the emergence of some skin tumors.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Basal Cell/pathology , Carcinoma, Squamous Cell/pathology , Hyperpigmentation/pathology , Melanoma/pathology , Skin Neoplasms/pathology , Stem Cell Factor/metabolism , Adult , Aged , Carcinoma, Basal Cell/metabolism , Carcinoma, Squamous Cell/metabolism , Case-Control Studies , Female , Follow-Up Studies , Humans , Hyperpigmentation/metabolism , Male , Melanoma/metabolism , Middle Aged , Prognosis , Skin Neoplasms/metabolism , Melanoma, Cutaneous Malignant
6.
Tissue Cell ; 57: 84-89, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30947969

ABSTRACT

Laryngeal cancer was identified as the second most common respiratory system malignancy with squamous cell carcinoma being the most common malignant tumor of the larynx. Larynx being a secondary sex organ showing physiological changes during puberty, raises inquiry about the relationship between sex hormones receptors as estrogen receptors (ER), progesterone receptors (PR), androgen receptors (AR) and the development of laryngeal carcinoma. This study was carried out in cancer tissue samples from 50 patients with laryngeal squamous cell carcinoma. Immunohistochemical staining using ER-ß, PR, and AR was carried out. The immunohistochemical expression of ER-ß, PR and AR was positive in 56%, 50% and 64% of cases respectively. ER-ß, and PR expression were significantly higher in poorly differentiated cases and cases with lymphatic invasion while AR expression was significantly lower in poorly differentiated cases and with lymphatic invasion. In conclusion, ER-ß and PR may be considered as markers for poor biological behavior of laryngeal carcinoma.


Subject(s)
Estrogen Receptor beta/biosynthesis , Laryngeal Neoplasms/pathology , Receptors, Androgen/biosynthesis , Receptors, Progesterone/biosynthesis , Squamous Cell Carcinoma of Head and Neck/pathology , Aged , Female , Humans , Laryngeal Neoplasms/metabolism , Male , Middle Aged , Prognosis , Squamous Cell Carcinoma of Head and Neck/metabolism
8.
Biomed Pharmacother ; 97: 667-674, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29101811

ABSTRACT

The aim of this study was to assess the effect of sitagliptin with or without resveratrol on carcinogen-induced clear cell renal cell carcinoma. Sixty male Wistar rats were divided into 6 equal groups as follows: control; clear cell renal cell carcinoma group; clear cell renal cell carcinoma+sitagliptin group; clear cell renal cell carcinoma+resveratrol group; clear cell renal cell carcinoma+carboxymethyl cellulose group and clear cell renal cell carcinoma+sitagliptin+resveratrol group. Blood urea, serum creatinine, creatinine clearance, urinary N-acetyl beta-d-glucosaminidase (NAG), gamma glutamyl transpeptidase (GGT) and urinary albumin excretion rate (UAER) were determined. Renal tissue antioxidant enzymes, lactate dehydrogenase (LDH), nuclear factor (erythroid-derived 2)-like 2 (Nrf2), heme oxygenase-1 (HO-1), transforming growth factor beta-1 (TGF-ß1), tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and signal transducers and activators of transcription-3 (STAT3) were determined. Parts of the kidneys were subjected to histopathological and immunohistochemical examination for nuclear factor kappa B (p65). Sitagliptin and/or resveratrol induced significant improvement of the renal functions with significant increase in tissue antioxidant defenses and Nrf2/HO-1 content associated with significant decrease in tissue LDH, TGF-ß1, TNF-α, IL-6 and STAT3 and alleviated the histopathological and immunohistochemical changes compared to the untreated clear cell renal cell carcinoma group. These effects were significant in sitagliptin/resveratrol combination group compared to the use of each of these drugs alone. In conclusion, sitagliptin/resveratrol combination might represent a beneficial therapeutic modality for amelioration of experimentally-induced clear cell renal cell carcinoma.


Subject(s)
Carcinoma, Renal Cell/drug therapy , Kidney Neoplasms/drug therapy , Sitagliptin Phosphate/pharmacology , Stilbenes/pharmacology , Animals , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Antioxidants/metabolism , Carcinoma, Renal Cell/pathology , Immunohistochemistry , Kidney Function Tests , Kidney Neoplasms/pathology , Male , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/pathology , Rats , Rats, Wistar , Resveratrol , Sitagliptin Phosphate/administration & dosage , Stilbenes/administration & dosage
9.
Environ Toxicol Pharmacol ; 50: 216-226, 2017 03.
Article in English | MEDLINE | ID: mdl-28192751

ABSTRACT

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted due to the authors' plagiarism of text and images from the work of Eman Said Abd-Elkhalek, Hatem Abdel-Rahman Salem, Ghada Mohamed SuddeK, Marwa Ahmed Zaghloul and Ramy Ahmed Abdel-Salam, Faculties of Pharmacy and Medicine, Mansoura University, Mansoura, Egypt.


Subject(s)
Bleomycin/toxicity , Calcitriol/analogs & derivatives , Linagliptin/administration & dosage , Pulmonary Fibrosis/prevention & control , Animals , Body Weight/drug effects , Calcitriol/administration & dosage , Calcitriol/pharmacology , Drug Therapy, Combination , In Vitro Techniques , Linagliptin/pharmacology , Male , Mice , Organ Size/drug effects , Pulmonary Fibrosis/chemically induced
10.
Asian Pac J Cancer Prev ; 17(4): 1769-72, 2016.
Article in English | MEDLINE | ID: mdl-27221850

ABSTRACT

BACKGROUND: Urothelial papilloma and non-invasive papillary carcinoma are common neoplasms of the urinary bladder. Distinguishing papillomas and papillary carcinomas, especially the low grade type, is often debatable on the basis of histological features alone. MATERIALS AND METHODS: We investigated immunohistochemical expression of cytokeratin 20 (CK20), p53, and Ki-67 in a group of 20 urothelial papilloma cases and 30 noninvasive papillary neoplasms of low malignant potential (PNLMP) of the urinary bladder. Whole tissue sections were examined. RESULTS: Among the 30 carcinoma cases, 12 (40%) showed strong reactivity for the whole panel, 16 (53%) reacted positively for two markers, and 2 (7%) reacted just to one of them. Ki-67 was considered positive in 27 cases (90%) and p53 in 24 (80%), CK20 showed positive reactivity in 21 cases (70%). Only small percentages of papillomas were positive, and then only weakly. CONCLUSIONS: We concluded that the intense positivity of suspicious cells for at least one of these markers would confirm the presence of malignant changes and favours the diagnosis of carcinoma.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Papillary/pathology , Cell Differentiation , Papilloma/pathology , Urinary Bladder Neoplasms/pathology , Urinary Bladder/pathology , Carcinoma, Papillary/metabolism , Case-Control Studies , Humans , Immunoenzyme Techniques , Keratin-20/metabolism , Ki-67 Antigen/metabolism , Neoplasm Invasiveness , Neoplasm Staging , Papilloma/metabolism , Prognosis , Tumor Suppressor Protein p53/metabolism , Urinary Bladder/metabolism , Urinary Bladder Neoplasms/metabolism
11.
Asian Pac J Cancer Prev ; 16(15): 6545-8, 2015.
Article in English | MEDLINE | ID: mdl-26434872

ABSTRACT

BACKGROUND: Synovial sarcoma is a mesenchymal neoplasm that accounts for around 10% of all soft tissue sarcomas. The diagnosis of synovial sarcoma can be a challenging task, particularly with small biopsy specimens. AIM: We investigated transducer-like enhancer of split 1 (TLE1), monoclonal antibody, expression by immunohistochemical analysis in a group of 74 synovial sarcoma cases, 20 cases of MPNST, 12 cases of neurofibroma, 15 cases of schwannoma, 5 cases of MFH, 10 cases of lieomyosarcoma and 10 cases of solitary fibrous tumor. MATERIALS AND METHODS: Whole tissue sections were examined: (39 biphasic and 35 monophasic). Nuclear immunoreactivity was scored as negative (<5% of cells positive), 1+(mild /5-25%), 2+ (moderate/25-50%), and 3+ (strong >50%). RESULTS: Overall, 71 (96%) of 74 synovial sarcomas were positive for TLE1, including 37 biphasic (95%) and 34 monophasic (97%) tumors. Other spindle cell tumors showed very low or absent staining of TLE1. CONCLUSIONS: We conclude that TLE1 is a sensitive marker and can be a useful diagnostic marker for synovial sarcoma, particularly the monophasic forms.


Subject(s)
Histiocytoma, Malignant Fibrous/chemistry , Leiomyosarcoma/chemistry , Neurilemmoma/chemistry , Neurofibroma/chemistry , Repressor Proteins/analysis , Sarcoma, Synovial/chemistry , Sarcoma, Synovial/diagnosis , Soft Tissue Neoplasms/chemistry , Soft Tissue Neoplasms/diagnosis , Solitary Fibrous Tumors/chemistry , Biomarkers, Tumor/analysis , Co-Repressor Proteins , Humans , Immunohistochemistry , Sarcoma, Synovial/pathology , Soft Tissue Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...